Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J. de la Piedra C, et al. Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30. Br J Cancer. 2013. PMID: 23722472 Free PMC article. Clinical Trial.
Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes.
González-San Segundo C, Jové J, Zapatero A, Pastor-Peidro J, Vázquez ML, Casaña M, Mengual JL, Gómez-Caamaño A, Gómez-Iturriaga A, Vallejo C, Henríquez I, Muñoz-García JL, Clemente J, Porras M, Collado E, Ossola G, Villafranca E, Cabeza MA, López-Torrecilla J. González-San Segundo C, et al. Clin Transl Oncol. 2019 Aug;21(8):1044-1051. doi: 10.1007/s12094-018-02021-7. Epub 2019 Jan 7. Clin Transl Oncol. 2019. PMID: 30617939
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study.
Angulo JC, Ciria Santos JP, Gómez-Caamaño A, Poza de Celis R, González Sala JL, García Garzón JM, Galán-Llopis JA, Pérez Sampietro M, Perrot V, Planas Morin J; ANARESISTANCE study group. Angulo JC, et al. World J Urol. 2022 Oct;40(10):2459-2466. doi: 10.1007/s00345-022-04108-x. Epub 2022 Sep 4. World J Urol. 2022. PMID: 36057895 Free PMC article.
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J, Boladeras A, Cabeza MA, Zapatero A, Jove J, Esteban LM, Henriquez I, Casaña M, González-San Segundo C, Gómez-Caamaño A, Mengual JL, Hervás A, Muñoz JL, Sanz G. López-Torrecilla J, et al. Strahlenther Onkol. 2015 Oct;191(10):792-800. doi: 10.1007/s00066-015-0866-7. Epub 2015 Jul 9. Strahlenther Onkol. 2015. PMID: 26156249
83 results